Peptic Ulcers Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update

Pages: 77 Published: November 30, 2021 Report Code: GMDGDHC13170IDB

  • Overview
  • Key Players
  • Contents
  • Tables
  • Figures
  • FAQ
  • Listen
    iSpeech.org

Peptic ulcers are open sores that develop on the inside lining of the esophagus, stomach, and the upper portion of the small intestine. Symptoms include nausea or vomiting, unexplained weight loss, appetite changes, and abdominal pain. Risk factors include smoking and alcoholism. It can be treated via antibiotics, acid blockers, antacids, and proton pump inhibitors.

The Peptic ulcers drugs in development market research report provides comprehensive information on the therapeutics under development for peptic ulcers, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for peptic ulcers and features dormant and discontinued projects.

What are the key targets in the peptic ulcers pipeline products market?

The key targets in the peptic ulcers pipeline products market are potassium transporting ATPase alpha chain 1 gastric H (+)/K, prostaglandin G/H synthase 2, cholinergic receptor muscarinic, epidermal growth factor receptor, histamine H2 receptor, and prostaglandin G/H synthase 1.

Peptic Ulcers Pipeline Products Analysis Market by Targets

Peptic Ulcers Pipeline Products Analysis Market by Targets

For more target insights, download a free report sample

What are the key mechanisms of action in the peptic ulcers pipeline products market?

The key mechanisms of action in the peptic ulcers pipeline products market are potassium transporting ATPase alpha chain 1 gastric H (+)/K inhibitor, prostaglandin G/H synthase 2 inhibitor, cholinergic receptor muscarinic antagonist, epidermal growth factor receptor agonist, histamine H2 receptor antagonist, and prostaglandin G/H synthase 1 inhibitor.

Peptic Ulcers Pipeline Products Market Analysis by Mechanism of Actions

Peptic Ulcers Pipeline Products Market Analysis by Mechanism of Actions

For more mechanism of actions insights, download a free report sample

What are the key routes of administration in the peptic ulcers pipeline products market?

The key routes of administration in the peptic ulcers pipeline products market are oral, intravenous, parenteral, and intravenous drip.

Peptic Ulcers Pipeline Products Market Analysis by Routes of Administration

Peptic Ulcers Pipeline Products Market Analysis by Routes of AdministrationFor more routes of administration insights, download a free report sample

What are the different molecule types in the peptic ulcers pipeline products market?

The different molecule types in the peptic ulcers pipeline products market are small molecule and fusion protein.

Peptic Ulcers Pipeline Products Market Analysis by Molecule Type

Peptic Ulcers Pipeline Products Market Analysis by Molecule Type

To know more about molecule types, download a free report sample

Which are the major companies in the peptic ulcers pipeline products market?

Some of the major companies in the peptic ulcers pipeline products market are Jiangsu Carephar Pharmaceutical Co Ltd, XuanZhu Biological Technology Co Ltd, Hunan Mingrui Pharmaceutical Co Ltd, Ilyang Pharmaceutical Co Ltd, Addpharma Inc, Axsome Therapeutics Inc, CalyGene Biotechnology Inc, Cinclus Pharma AG, Daewoong Pharmaceutical Co Ltd, and Edenbridge Pharmaceuticals LLC.

Peptic ulcers Pipeline Products Market Analysis by Companies

Peptic ulcers Pipeline Products Market Analysis by Companies

To know more about major companies, download a free report sample

Market Report Scope

Key targets Potassium Transporting ATPase Alpha Chain 1 Gastric H (+)/K, Prostaglandin G/H Synthase 2, Cholinergic Receptor Muscarinic, Epidermal Growth Factor Receptor, Histamine H2 Receptor, and Prostaglandin G/H Synthase 1
Key mechanism of action Potassium Transporting ATPase Alpha Chain 1 Gastric H (+)/K Inhibitor, Prostaglandin G/H Synthase 2 Inhibitor, Cholinergic Receptor Muscarinic Antagonist, Epidermal Growth Factor Receptor Agonist, Histamine H2 Receptor Antagonist, and Prostaglandin G/H Synthase 1 Inhibitor
Key routes of administration Oral, Intravenous, Parenteral, and Intravenous Drip
Molecule type Small Molecule and Fusion Protein
Major companies Jiangsu Carephar Pharmaceutical Co Ltd, XuanZhu Biological Technology Co Ltd, Hunan Mingrui Pharmaceutical Co Ltd, Ilyang Pharmaceutical Co Ltd, Addpharma Inc, Axsome Therapeutics Inc, CalyGene Biotechnology Inc, Cinclus Pharma AG, Daewoong Pharmaceutical Co Ltd, and Edenbridge Pharmaceuticals LLC

Scope

  • The report provides a snapshot of the global therapeutic landscape of peptic ulcers
  • The report reviews pipeline therapeutics for peptic ulcers by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in peptic ulcers therapeutics and enlists all their major and minor projects
  • The report assesses peptic ulcers therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA), and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews the latest news related to pipeline therapeutics for peptic ulcers

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with a potentially strong product portfolio and create effective counter-strategies to gain a competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for peptic ulcers
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding peptic ulcers pipeline depth and focus on Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from the pipeline

Key Players

Addpharma Inc

Axsome Therapeutics Inc

CalyGene Biotechnology Inc

Cinclus Pharma AG

Daewoong Pharmaceutical Co Ltd

Edenbridge Pharmaceuticals LLC

FortuneRock (China) Ltd

Hunan Mingrui Pharmaceutical Co Ltd

Hunan Sailong Pharmaceutical Co Ltd

Ilyang Pharmaceutical Co Ltd

Jiangsu Aosaikang Pharmaceutical Co Ltd

Jiangsu Carephar Pharmaceutical Co Ltd

Korea Pharma Co Ltd

Kukje Pharmaceutical Industry Co Ltd

PharmaKing Co Ltd

PharmGen Science Inc

RaQualia Pharma Inc

Sotex Pharm Firm

XuanZhu Biological Technology Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Peptic Ulcers – Overview

Peptic Ulcers – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Peptic Ulcers – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Peptic Ulcers – Companies Involved in Therapeutics Development

Addpharma Inc

Axsome Therapeutics Inc

CalyGene Biotechnology Inc

Cinclus Pharma AG

Daewoong Pharmaceutical Co Ltd

Edenbridge Pharmaceuticals LLC

FortuneRock (China) Ltd

Hunan Mingrui Pharmaceutical Co Ltd

Hunan Sailong Pharmaceutical Co Ltd

Ilyang Pharmaceutical Co Ltd

Jiangsu Aosaikang Pharmaceutical Co Ltd

Jiangsu Carephar Pharmaceutical Co Ltd

Korea Pharma Co Ltd

Kukje Pharmaceutical Industry Co Ltd

PharmaKing Co Ltd

PharmGen Science Inc

RaQualia Pharma Inc

Sotex Pharm Firm

XuanZhu Biological Technology Co Ltd

Peptic Ulcers – Drug Profiles

(meloxicam + esomeprazole) – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AD-214 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CG-20043 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dexlansoprazole – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dexlansoprazole – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

famotidine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fexuprazan – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glycopyrrolate – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ilaprazole DR – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INT-2150 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IYIC-062 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KBP-3571 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

konolazan hydrochloride – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KP-201 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

linaprazan glurate – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pantoprazole sodium – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PMKS-005 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rabeprazole sodium – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SFR-9X0123 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit COX-2 for Gastric Ulcers, Inflammation and Pain – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tegoprazan – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vonoprazan acetate – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

WRDN-002 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptic Ulcers – Dormant Projects

Peptic Ulcers – Discontinued Products

Peptic Ulcers – Product Development Milestones

Featured News & Press Releases

Oct 22, 2021: Sihuan Pharmaceutical Holdings Group: New Drug Application of Xuanzhu Biopharm’s drug Anaprazole Sodium accepted by NMPA

Mar 12, 2020: Gastroesophageal reflux disease new drug K-cap, Helicobacter pylori eradication indication

Feb 13, 2020: Sihuan Pharmaceutical Holdings Group: Commencement of phase III clinical trial in the PRC for self-developed innovative patented drug Anaprazole Sodium

Apr 25, 2019: Sihuan Pharm’s innovative digestive system drug Anaprazole Sodium achieved early completion of patient recruitment for phase II clinical trial in China

Jul 17, 2013: Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole Sodium Category

1.1 New Drug Clinical Studies

Jul 27, 2011: Ilyang Pharmaceuticals Obtains Patent For Ilaprazole

Mar 01, 2010: AstraZeneca Provides An Update On The Status Of Its Arrangements With Merck

Mar 01, 2010: AstraZeneca Provides An Update On The Status Of Its Arrangements With Merck

Jan 07, 2010: AstraZeneca Reaches Agreements With Teva Pharmaceuticals Regarding Nexium And Prilosec US Patent Litigations

Jan 07, 2010: AstraZeneca Reaches Agreements With Teva Pharmaceuticals Regarding Nexium And Prilosec US Patent Litigations

Apr 15, 2008: AstraZeneca Settles US Nexium Patent Litigation with Ranbaxy

Apr 15, 2008: AstraZeneca Settles US Nexium Patent Litigation with Ranbaxy

Feb 28, 2008: AstraZeneca Provides An Update on the Status of its Arrangements With Merck & Co., Inc.

Feb 28, 2008: AstraZeneca Provides An Update on the Status of its Arrangements With Merck & Co., Inc.

Dec 10, 2007: FDA Concludes There Is No Increased Risk Of Cardiac Events For Patients Treated With Omeprazole And NEXIUM (Esomeprazole Magnesium)

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Peptic Ulcers, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Peptic Ulcers – Pipeline by Addpharma Inc, 2021

Peptic Ulcers – Pipeline by Axsome Therapeutics Inc, 2021

Peptic Ulcers – Pipeline by CalyGene Biotechnology Inc, 2021

Peptic Ulcers – Pipeline by Cinclus Pharma AG, 2021

Peptic Ulcers – Pipeline by Daewoong Pharmaceutical Co Ltd, 2021

Peptic Ulcers – Pipeline by Edenbridge Pharmaceuticals LLC, 2021

Peptic Ulcers – Pipeline by FortuneRock (China) Ltd, 2021

Peptic Ulcers – Pipeline by Hunan Mingrui Pharmaceutical Co Ltd, 2021

Peptic Ulcers – Pipeline by Hunan Sailong Pharmaceutical Co Ltd, 2021

Peptic Ulcers – Pipeline by Ilyang Pharmaceutical Co Ltd, 2021

Peptic Ulcers – Pipeline by Jiangsu Aosaikang Pharmaceutical Co Ltd, 2021

Peptic Ulcers – Pipeline by Jiangsu Carephar Pharmaceutical Co Ltd, 2021

Peptic Ulcers – Pipeline by Korea Pharma Co Ltd, 2021

Peptic Ulcers – Pipeline by Kukje Pharmaceutical Industry Co Ltd, 2021

Peptic Ulcers – Pipeline by PharmaKing Co Ltd, 2021

Peptic Ulcers – Pipeline by PharmGen Science Inc, 2021

Peptic Ulcers – Pipeline by RaQualia Pharma Inc, 2021

Peptic Ulcers – Pipeline by Sotex Pharm Firm, 2021

Peptic Ulcers – Pipeline by XuanZhu Biological Technology Co Ltd, 2021

Peptic Ulcers – Dormant Projects, 2021

Peptic Ulcers – Dormant Projects, 2021 (Contd..1)

Peptic Ulcers – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Peptic Ulcers, 2021

Number of Products under Development by Companies, 2021

Number of Products by Targets, 2021

Number of Products by Stage and Targets, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

Frequently Asked Questions

The key targets in the peptic ulcers pipeline products market are potassium transporting ATPase alpha chain 1 gastric H (+)/K, prostaglandin G/H synthase 2, cholinergic receptor muscarinic, epidermal growth factor receptor, histamine H2 receptor, and prostaglandin G/H synthase 1.

The key mechanisms of action in the peptic ulcers pipeline products market are potassium transporting ATPase alpha chain 1 gastric H (+)/K inhibitor, prostaglandin G/H synthase 2 inhibitor, cholinergic receptor muscarinic antagonist, epidermal growth factor receptor agonist, histamine H2 receptor antagonist, and prostaglandin G/H synthase 1 inhibitor.

The key routes of administration in the peptic ulcers pipeline products market are oral, intravenous, parenteral, and intravenous drip.

The different molecule types in the peptic ulcers pipeline products market are small molecule and fusion protein.

Some of the major companies in the peptic ulcers pipeline products market are Jiangsu Carephar Pharmaceutical Co Ltd, XuanZhu Biological Technology Co Ltd, Hunan Mingrui Pharmaceutical Co Ltd, Ilyang Pharmaceutical Co Ltd, Addpharma Inc, Axsome Therapeutics Inc, CalyGene Biotechnology Inc, Cinclus Pharma AG, Daewoong Pharmaceutical Co Ltd, and Edenbridge Pharmaceuticals LLC.

$2000

Can be used by individual purchaser only

$6000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.